175TH CONGRESS
2ND SESSION
H. R. 20
Toaddressthe rapidlygrowing drug
epidemicinthe UnitedStates,and for
otherpurposes.
INTHEHOUSE OF REPRESENTATIVES
May4,2024
Mr.Willow of Pacificaintroduced thefollowing bill;
A BILL
ToreinstatetheDrug Enforcement Administrationandthe ControlledSubstancesAct,enact
programs for medication-assisted therapyfor individuals withopioiduse disorders,and
reschedulecertain drugs.
Beit enactedbytheSenateandHouse ofRepresentativesof theUnited StatesofAmericain
Congressassembled,

SECTION 1.SHORTTITLE.
This Actmaybe citedas the“Combating the DrugEpidemic Actof 2024”.
SEC.2.FINDINGS.
SEC.3.REINSTATEMENTOF THE CSAANDDEA.
(a) IN GENERAL.—Sec.4(a) and4(b) ofthe Addiction isNotaCrime Actof 2020arehereby
repealed. TheDrugEnforcementAdministration(DEA) shallresumenormaloperation
uponappointment bythePresident ofits Administratorand subsequentconfirmationby
theSenate.
(b) Upon reinstatement ofthe DEA,the Administration’simmediatepriority shallbeto
identify thevolume ofdrugs currentlybeing shippedinto andoutof theUnited States,
and whatgroups (i.e.cartels) areresponsiblefor thesynthesis andimportation of such
drugs. TheDEAshallthen takeall measuresnecessarytoprevent theimportation of
narcotics,specifically illicit fentanyl.Forthe first year,the DEAshallexplicitly avoid
focusing onheroinimportation.
SEC.4.CSA REFORM.
(a) 21U.S. Code §844is herebyrepealed.
(b) 21U.S. Code §812is amendedasfollows:
(i) Bystriking subsection (b)(1)

(ii) Bymoving the contentsofsubsection (c)(1)tosubsection (c)(2)andrenumbering
section (c)(2) assection(c)(1) andall othersectionsas follows,withtheexception
of thefollowing itemswhich shallbestruckentirely:
(1) 3,4-methylenedioxyamphetamine.
(2) 5-methoxy-3,4-methylenedioxyamphetamine.
(3) 3,4,5-trimethoxyamphetamine.
(4) Bufotenine.
(5) Diethyltryptamine.
(6) Dimethyltryptamine.
(7) 4-methyl-2,5-dimethoxyamphetamine.
(8) Ibogaine.
(9) Lysergic acid diethylamide.
(10) Marihuana.
(11) Mescaline.
(12) N-ethyl-3-piperidyl benzilate.
(13) N-methyl-3-piperidyl benzilate.
(14) Psilocybin.
(15) Psilocyn.
(16) Tetrahydrocannabinols,exceptfor tetrahydrocannabinols inhemp (as
definedunder section1639oof title7).
(17) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E).
(18) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine(2C–D).
(19) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C).

(20) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I).
(21) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2).
(22) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine(2C–T–4).
(23) 2-(2,5-Dimethoxyphenyl)ethanamine(2C–H).
(24) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N).
(25) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine(2C–P).
(iii) Byamending section(b) toreadas follows:
“Except where controlisrequired byUnited Statesobligationsunder an
international treaty,convention,orprotocol, ineffect onOctober27,1970,and
exceptin the caseofan immediateprecursor,a drugor othersubstancemay not
be placedin anyscheduleunlessthe findingsrequired for suchschedulearemade
with respecttosuch drugor othersubstance,and theprimaryeffect ofthe drug
isnot hallucinogenic viaagonism ofthe human5-HT2Areceptor.The
findings requiredfor each ofthe schedulesareas follows:”
(iv) Byinsertingitem(12) under subsection (c)(4)readingas follows:
“Xylazine (N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine)”
(v) Byinsertingunder the respectivesubsections (c)(1-4)representing schedulesII-V
respectively eachitemthat wasin 21CFR1308prior totheenactment of the
Addiction isNota CrimeAct of2020inthe scheduleit waslocatedwithin atthat
time,with allitemsfalling under 21CFR1308.11being placedunder subsection
(c)(1) representing Schedule II, withtheexception ofall itemsfalling under21
CFR 1308.11(d) whichshallbestruck entirely,withthe exceptionof the
following itemswhich shallbeplacedunder 21USC§812(c)(1):

(1) Peyote.
(2) Ethylamineanalog of phencyclidine
(3) Pyrrolidine analog ofphencyclidine
(4) Thiophene analogof phencyclidine
(5) 4-methylmethcathinone (Mephedrone)
(6) 3,4-methylenedioxypyrovalerone(MDPV)
(7) 3,4-Methylenedioxy-N-methylcathinone(Methylone)
(8) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
(UR-144)
(9) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)metha
none(5-fluoro-UR-144, XLR11)
(10) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide(APINACA,
AKB48)
(11) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22;QUPIC)
(12) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
(5-fluoro-PB-22; 5F-PB-22)
(13) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazol
e-3-carboxamide(AB-FUBINACA)
(14) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-ca
rboxamide (ADB-PINACA)
(15) 4-methyl-N-ethylcathinone(4-MEC)
(16) 4-methyl-alpha-pyrrolidinopropiophenone
(17) alpha-pyrrolidinopentiophenone (α-PVP)

(18) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone,
bk-MBDB)
(19) 2-(methylamino)-1-phenylpentan-1-one (pentedrone)
(20) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone,
bk-MBDP)
(21) 4-fluoro-N-methylcathinone (4-FMC;flephedrone)
(22) 3-fluoro-N-methylcathinone (3-FMC)
(23) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone)
(24) alpha-pyrrolidinobutiophenone (α-PBP)
(25) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-inda
zole-3-carboxamide (AB-CHMINACA)
(26) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carbo
xamide(AB-PINACA)
(27) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone
(THJ-2201)
(28) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-i
ndazole-3-carboxamide(MAB-CHMINACA; ADB-CHMINACA)
(29) methyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
(Othernames: 5F-ADB;5F-MDMB-PINACA)
(30) methyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
(Othernames: 5F-AMB)

(31) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
(Othernames: 5F-APINACA, 5F-AKB48)
(32) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-ind
azole-3-carboxamide(Othernames: ADB-FUBINACA)
(33) methyl
2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoat
e (Other names:MDMB-CHMICA,MMB-CHMINACA)
(34) methyl
2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
(Othernames: MDMB-FUBINACA)
(35) methyl
2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,
(FUB-AMB, MMB-FUBINACA,AMB-FUBINACA)
(36) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (ethylone)7547
(81) Naphthalen-1-yl1-(5-fluoropentyl)-1H-indole-3-carboxylate(Other
names:NM2201; CBL2201)
(37) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazol
e-3-carboxamide(Other name:5F-AB-PINACA)
(38) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamid
e (Other names:4-CN-CUMYL-BUTINACA;
4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA;
CUMYL-4CN-BINACA;SGT-78)

(39) methyl
2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate
(Othernames: MMB-CHMICA;AMB-CHMICA)
(40)
1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-
carboxamide(Othername:5F-CUMYL-P7AICA)
(41) N-ethylpentylone(Othernames:ephylone,
1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one)
(42) methyl
2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
(4F-MDMB-BINACA, 4F-MDMB-BUTINACA)
(43) 1-(4-methoxyphenyl)-N-methylpropan-2-amine (othernames:
para-methoxymethamphetamine,PMMA) (1245) (89) ethyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
(other name:5F-EDMB-PINACA)
(44) methyl
2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
(other names:5F-MDMB-PICA;5F-MDMB-2201)
(45) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(other names:FUB-AKB48; FUB-APINACA;AKB48
N-(4-FLUOROBENZYL))
(46) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxami
de (other names:5F-CUMYL-PINACA; SGT-25)

(47) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)me
thanone (othername:FUB-144)
(48) N-Ethylhexedrone (Othernames:α-ethylaminohexanophenone;
2-(ethylamino)-1-phenylhexan-1-one)
(49) alpha-Pyrrolidinohexanophenone(Other names:α-PHP;
α-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one)
(50) 4-Methyl-alpha-ethylaminopentiophenone (Othernames:4-MEAP;
2-(ethylamino)-1-(4-methylphenyl)pentan-1-one)
(51) 4′-Methyl-alpha-pyrrolidinohexiophenone (Othernames:MPHP;
4′-methyl-alpha-pyrrolidinohexanophenone;
1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one)
(52) alpha-Pyrrolidinoheptaphenone (Othernames:PV8;
1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one)
(53) 4′-Chloro-alpha-pyrrolidinovalerophenone(Othernames:
4-chloro-α-PVP;4′-chloro-α-pyrrolidinopentiophenone;
1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one)
(54) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one (othernames:
eutylone;bk-EBDB)
(55) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-car
boxamide(other name:ADB-BUTINACA)
(56) 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (other names:
α-PiHP; alpha-PiHP)

(57) 2-(methylamino)-1-(3-methylphenyl)propan-1-one(other names:
3-MMC; 3-methylmethcathinone)
SEC.5.AMENDMENTS TOTHE CFRREGARDINGOPIOIDAGONIST THERAPY.
(a) 42CFR §8.12isamendedas follows:
(i) Byreplacing“and that thepersonbecameaddicted atleast1yearbefore
admissionfor treatment”insubsection (e)with“and that thepersonbecame
addicted at least6months beforeadmission for treatment,orthat the person’s
addiction iscausingor islikely toimminently (in thenext 6months)cause
severeand tangibledamage totheircareer,education, finances, or
relationships.”
(ii) Byinsertingin subsection(h)(2) after thelistof currentlyapprovedopioidagonist
treatment medicationsthe following text:“AnOTPwishing tomake useof
narcotics(asdefinedin 21USC§802,withtheexception ofcocaine) otherthan
those specified abovemust send anapplication totheDrug Enforcement
Administrationdetailing thereasons for useof thedrug andstepstobe takento
prevent diversion. If this applicationis accepted,the OTPmay usethe narcotic
specifiedinthe application for maintenanceordetoxification therapy.TheDEA
mayalso license individualOTPs touseothernarcoticswithout application ofits
own accord.SuchOTPs willbereferred toas OTPsusing alternativenarcotics.”
(iii) Byaddingsubsection (k) following subsection(j)to readasfollows:
(k) Methadone prescriptionsbyprivate practitioners:A licensedphysiciancurrentlypracticing
with noactivelimitations on theirlicense andboard certifiedinaddiction psychiatrymay

prescribe methadonefor thepurposesof opioiddetoxification and/ormaintenanceaslong asthe
following conditions aremet:
(i) Theprescriberisin possessionof aDEAX waiver,
(ii) Theprescriber followsall otherrequirements expectedof anOTPthat couldbe reasonably
fulfilled byasinglephysician (supervisedpharmacy dosinguntil stability,urinedrug screens,
etc.),
(iii) Theprescriberreportsyearly totheDEA stepsbeingtaken topreventdiversion of
methadone prescribedfor treatment ofOUD.
(iv) Bystriking subsection (i)(3).
(b) Within 90daysfromthe enactment ofthis Act,the DEAshalllicenseat leastoneOTP in
thecountryto provide treatmentwitheach of thefollowing narcotics:
(i) Morphine
(ii) Diacetylmorphine (Heroin)
(iii) Hydromorphone
(iv) Oxycodone
(v) Oxymorphone
(c) In thefirst threeyearsof thepassage ofthis Act,the DEAshallobtain thefollowing data
from arepresentative sampleof OTPs(and prescribersactivelyprescribing methadone
under 42CFR§8.12(k)) as wellas fromtheOTPs usingalternative narcotics:
(i) Patientretention.
(ii) Amount of non-prescribed illicitdrugs inurinesamples.
(iii) Number ofpatients definedas “stable”
(iv) Continued patient employment.

(v) Patientoverdosedeaths.
(d) Attheend of three years,theDEA shallwriteareportonthe data receivedunder
subsection(c).
SEC.5.EXPLICIT APPLICATION OF FRAUDLAW TOILLICITDRUG SALES
WHENINTERSTATE COMMERCEISINVOLVED.
(a) 18U.S. Code §1341is amendedtoreadas follows:
“Whoever,havingdevised orintendingtodeviseany schemeorartifice todefraud, orfor
obtainingmoneyor property bymeansoffalse orfraudulentpretenses,representations,or
promises, or tosell,dispose of,loan, exchange,alter,giveaway,distribute,supply,or furnishor
procurefor unlawfuluseanycounterfeit orspurious coin,obligation,security, psychoactive
substance, or otherarticle,or anything representedtobe orintimated orheld outtobe such
counterfeitor spurious article,for the purposeofexecuting suchschemeor artificeor attempting
so todo,places inany post officeor authorized depositoryfor mailmatter,any matteror thing
whatever tobe sentor delivered bythePostal Service,or depositsor causestobedeposited any
matter or thing whatevertobe sentor delivered byanyprivateor commercialinterstate carrier,
or takesor receivestherefrom, anysuchmatter or thing,or knowinglycausestobe deliveredby
mailor suchcarrieraccordingtothe direction thereon,orat theplaceat whichit isdirected tobe
delivered bythepersonto whomitis addressed,any suchmatter orthing, shallbefinedunder
this titleor imprisoned not morethan20years,or both.If the violationoccursinrelation to,or
involving anybenefitauthorized,transported, transmitted,transferred,disbursed, orpaid in
connection with,a presidentially declaredmajor disasteroremergency (asthoseterms are
defined insection 102of the RobertT. Stafford DisasterReliefand EmergencyAssistanceAct

(42 U.S.C.5122)), or affectsafinancialinstitution, such personshallbefinednotmorethan
$1,000,000or imprisonednot morethan30years,or both.”
SEC.6.SEVERABILITY.
Should any portion of this Actbedeemedinvalidor unconstitutionalfor anyreasonin acourt
with relevantjurisdiction,the restof theAct,and theapplication ofthe remaining provisions,
shallnot beaffected.
SEC.7.APPROPRIATIONS
(a) There isauthorizedtobe appropriatedaone-time sumof $2,000,000,000 for theinitial
reinstatementof theDrugEnforcementAdministration, andits operationsuntil Dec.31,
2024.
(b) There isauthorizedtobe appropriatedanadditional sumof $100,000,000for the
purposes outlinedin Sec.3(b).
SEC.8.EFFECTIVE DATE.
This Actshalltake effectimmediatelyuponits signature intolaw.